GlobalData on MSN2d
Gilead and MSD to advance once-weekly HIV treatment to Phase IIIThe companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Zacks.com on MSN3d
Gilead, MRK Report Data From Investigational Combination Study for HIVGilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...
Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...
Maharashtra launches a groundbreaking 28-day TB treatment for HIV patients aiming to reduce mortality and improve healthcare ...
Progress has been made in HIV care. However, that doesn’t mean you don’t need a detailed plan for taking care of an ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Two posters compared health care resource utilization (HCRU) and financial burdens of people living with HIV with a non-HIV ...
Alchemy, which sets up pharmacies in community clinics, said that it had raised $31 million from Andreessen Horowitz and ...
Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden ...
Namibia has made significant strides in stemming the spread of HIV and AIDS through education and prevention. However, for people like Anna Engomba, the arrival of new, life-saving medication cannot ...
The availability of such kidney transplants outside of the research setting could substantially improve organ availability ...
A new study published in the Journal of Clinical Tuberculosis and Other Mycobacterial Diseases showed that two ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback